Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: HeyRainier who wrote (8451)	8/14/1998 10:16:00 AM
From: MarkM	Respond to of 9262

Is SEG starting a breakout now? Ask $26.5, last sale $26.4375. Good upgrades and news lately. Incredible strength this morning. Next stop $28 range. Today???

To: HeyRainier who wrote (8451)	8/15/1998 3:33:00 AM
From: freelyhovering	Respond to of 9262

Me too. Myron

To: HeyRainier who wrote (8451)	9/1/1998 12:26:00 PM
From: scaram(o)uche	Respond to of 9262

[ biofreaks ] Ray/Carol/Rainier/others with a bio interest...... Well, after our bio trading successes early this year, some of you know that biotech freaks have been fed their butt on a platter in the past three months. BTRN.... selling at below cash/share in-hand. Phase II clinical trials ongoing with partner MEDI, addressing large markets. Upside potential? 5X or so if the phase II data is strong, time frame one year. Downside? None for at least 12 months, IMO. SIBI.... selling at below cash/share in-hand. Lots of clinicals either ongoing or about to start. Huge markets addressed with partners (BMY and Novartis), VGCC-pain program not partnered and quite promising, non-partnered programs in clinic are crap-shoots. Upside potential? 10X within one year if two or more programs go well and attract attention (SIBI has one of the most comprehensive Alzheimer's programs..... AChR receptors, beta amyloid processing, and caspases). Unlikely, some would say. Downside? Failure is already in the share price for the ongoing clinical trials. Cash burn could lead to further erosion in share price over the next year, but that would also, IMO, assume that the VGCC-pain program could not be partnered. Unlikely, IMO. Disclaimer.... I own these suckers, and have a vested interest in their appreciation. Warning...... due to margin calls and earlier assumptions (as listed above) about restricted downside, I don't have as large a vested interest as I used to have. ;-( Cheers! Rick